Blog
RSS FeedPosted by Michael Wonder on 13 Mar 2020
ICER releases evidence report on treatments for sickle cell disease
12 March 2020 - Three new treatments use different mechanisms to improve patient outcomes, offering important options for patients. ...
Posted by Michael Wonder on 03 Mar 2020
ICER to postpone assessment of gene therapy for beta thalassemia
3 March 2020 - Due to delay in regulatory submission, ICER will reinitiate assessment at a future date — ...
Posted by Michael Wonder on 25 Feb 2020
ICER issues final report and policy recommendations on acute treatments for migraine
25 February 2020 - Evidence on new agents lasmiditan, ubrogepant, and rimegepant judged inadequate to demonstrate superiority over more affordable triptans. ...
Posted by Michael Wonder on 24 Feb 2020
Drug pricing review group signs deal with Aetion for patient data
24 February 2020 - The Institute for Clinical and Economic Review (ICER), a small but influential Boston-based research group, has ...
Posted by Michael Wonder on 24 Feb 2020
ICER and Aetion partner to develop real-world evidence for value assessment of treatments
24 February 2020 - ICER adopts Aetion’s Real-World Evidence Platform — advancing standards for the use of transparent, replicable real-world ...
Posted by Michael Wonder on 24 Feb 2020
ICER to assess evidence on supervised injection facilities and digital apps for opioid use disorder
21 February 2020 - ICER expands its reviews in area of ongoing public health crisis related to opioid addiction. ...
Posted by Michael Wonder on 20 Feb 2020
ICER to assess treatments for bladder cancer
20 February 2020 - Report will be subject of a Midwest CEPAC meeting in September 2020; open Input now being ...
Posted by Michael Wonder on 20 Feb 2020
ICER releases draft evidence report on therapies for cystic fibrosis
20 February 2020 - Public comment period now open until 18 March 2020; requests to make oral comment during public meeting ...
Posted by Michael Wonder on 12 Feb 2020
ICER methods could be illegal in US, claims US think tank
11 February 2020 - The method used by the US Institute for Clinical and Economic Review (ICER) to gauge whether ...
Posted by Michael Wonder on 02 Feb 2020
ICER finalises 2020 updates to methods and public meeting procedures for value assessment framework
31 January 2020 - Reflecting experience with previous framework, benchmarking with other HTA groups, and input from more than 100 organisations ...
Posted by Michael Wonder on 25 Jan 2020
ICER posts draft scoping document for the assessment of treatments for haemophilia A
24 January 2020 - Document open to public comment until 13 February 2020. ...
Posted by Michael Wonder on 24 Jan 2020
ICER releases draft evidence report on therapies for sickle cell disease
23 January 2020 - ICER’s ongoing assessment emphasises that policy makers will need to consider, in addition to traditional measures ...
Posted by Michael Wonder on 10 Jan 2020
ICER releases evidence report on acute treatments for migraine
10 January 2020 - Lasmiditan, rimegepant, and ubrogepant all perform better than placebo, but evidence is not adequate to distinguish among ...
Posted by Michael Wonder on 09 Jan 2020
ICER issues final report and policy recommendations on JAK inhibitors for rheumatoid arthritis
9 January 2020 - Despite upadacitinib reaching common thresholds for cost-effectiveness when compared to adalimumab, the independent appraisal committee’s votes on ...
Posted by Michael Wonder on 06 Jan 2020
ICER posts draft scoping document for the assessment of treatments for beta thalassaemia
6 January 2020 - Document open to public comment until 27 January 2020. ...